The company plans to evaluate its Allurion Program with GLP-1 agonists to address muscle loss concerns and promote healthier weight loss. Allurion entered into a securities purchase agreement to ...
Allurion Technologies, Inc. develops treatments for obesity. The Allurion Program is a weight loss platform that combines the Allurion Gastric Balloon, a swallowable, procedure-less gastric ...
Hosted on MSN1mon
Allurion announces study on obesity treatment enhancementThe study will explore the combination of the Allurion Program, including the Allurion Balloon and Virtual Care Suite, with GLP-1 agonists to potentially improve muscle mass retention and overall ...
Hosted on MSN1mon
Allurion secures new patent for gastric balloon technologyNATICK, Mass. - Allurion Technologies, Inc. (NYSE: ALUR), a company focused on obesity treatment solutions, has expanded its intellectual property portfolio with a newly issued U.S. patent.
Allurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-lessTM ...
Allurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less TM ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback